RVNC - Revance Therapeutics EPS misses by $0.12 misses on revenue August, 06 2020 04:31 PM Revance Therapeutics Inc. Revance Therapeutics (NASDAQ:RVNC): Q2 GAAP EPS of -$1.12 misses by $0.12.More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...